JPWO2021035054A5 - - Google Patents

Download PDF

Info

Publication number
JPWO2021035054A5
JPWO2021035054A5 JP2022510857A JP2022510857A JPWO2021035054A5 JP WO2021035054 A5 JPWO2021035054 A5 JP WO2021035054A5 JP 2022510857 A JP2022510857 A JP 2022510857A JP 2022510857 A JP2022510857 A JP 2022510857A JP WO2021035054 A5 JPWO2021035054 A5 JP WO2021035054A5
Authority
JP
Japan
Prior art keywords
cells
genetically modified
antibody
population
subject
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2022510857A
Other languages
English (en)
Japanese (ja)
Other versions
JP2022544825A (ja
JP2022544825A5 (https=
Publication date
Application filed filed Critical
Priority claimed from PCT/US2020/047202 external-priority patent/WO2021035054A1/en
Publication of JP2022544825A publication Critical patent/JP2022544825A/ja
Publication of JPWO2021035054A5 publication Critical patent/JPWO2021035054A5/ja
Publication of JP2022544825A5 publication Critical patent/JP2022544825A5/ja
Pending legal-status Critical Current

Links

JP2022510857A 2019-08-20 2020-08-20 細胞免疫療法のためのリンパ球枯渇投与レジメン Pending JP2022544825A (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201962889338P 2019-08-20 2019-08-20
US62/889,338 2019-08-20
US202063061070P 2020-08-04 2020-08-04
US63/061,070 2020-08-04
PCT/US2020/047202 WO2021035054A1 (en) 2019-08-20 2020-08-20 Lymphodepletion dosing regimens for cellular immunotherapies

Publications (3)

Publication Number Publication Date
JP2022544825A JP2022544825A (ja) 2022-10-21
JPWO2021035054A5 true JPWO2021035054A5 (https=) 2023-08-29
JP2022544825A5 JP2022544825A5 (https=) 2023-08-29

Family

ID=72291163

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2022510857A Pending JP2022544825A (ja) 2019-08-20 2020-08-20 細胞免疫療法のためのリンパ球枯渇投与レジメン

Country Status (6)

Country Link
US (1) US20220273720A1 (https=)
EP (1) EP4017526A1 (https=)
JP (1) JP2022544825A (https=)
AU (1) AU2020333851A1 (https=)
CA (1) CA3148179A1 (https=)
WO (1) WO2021035054A1 (https=)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2020232691B2 (en) 2019-03-05 2023-06-29 Nkarta, Inc. CD19-directed chimeric antigen receptors and uses thereof in immunotherapy
KR20240032732A (ko) * 2021-05-13 2024-03-12 엔카르타, 인크. 암 면역요법을 위한 투약 요법
CA3219473A1 (en) * 2021-05-24 2022-12-01 Francisco Leon Methods for treating post infectious autoimmune diabetes
US12565529B2 (en) 2021-05-24 2026-03-03 Provention Bio, Inc. Methods for treating type 1 diabetes
US20250009800A1 (en) * 2021-11-16 2025-01-09 Precision Biosciences, Inc. Methods for cancer immunotherapy
US20250041417A1 (en) * 2021-12-10 2025-02-06 Precision Biosciences, Inc. Methods for cancer immunotherapy
AU2024337370A1 (en) * 2023-09-08 2026-02-26 Fate Therapeutics, Inc. Ipsc-derived effector cells for autoimmune disease treatment

Family Cites Families (53)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5585362A (en) 1989-08-22 1996-12-17 The Regents Of The University Of Michigan Adenovirus vectors for gene therapy
US5350674A (en) 1992-09-04 1994-09-27 Becton, Dickinson And Company Intrinsic factor - horse peroxidase conjugates and a method for increasing the stability thereof
US6140466A (en) 1994-01-18 2000-10-31 The Scripps Research Institute Zinc finger protein derivatives and methods therefor
DE69534629D1 (de) 1994-01-18 2005-12-29 Scripps Research Inst Derivate von zinkfingerproteinen und methoden
GB9824544D0 (en) 1998-11-09 1999-01-06 Medical Res Council Screening system
ATE524545T1 (de) 1994-08-20 2011-09-15 Gendaq Ltd Verbesserungen bei oder im zusammenhang mit bindeproteinen zur erkennung von dna
US5789538A (en) 1995-02-03 1998-08-04 Massachusetts Institute Of Technology Zinc finger proteins with high affinity new DNA binding specificities
US7696338B2 (en) 1995-10-30 2010-04-13 The United States Of America As Represented By The Department Of Health And Human Services Immunotoxin fusion proteins and means for expression thereof
US5925523A (en) 1996-08-23 1999-07-20 President & Fellows Of Harvard College Intraction trap assay, reagents and uses thereof
GB9710809D0 (en) 1997-05-23 1997-07-23 Medical Res Council Nucleic acid binding proteins
EP1958962A3 (en) 1997-06-12 2013-05-01 Novartis International Pharmaceutical Ltd. Artificial antibody polypeptides
US6015832A (en) 1997-12-31 2000-01-18 The Regents Of The University Of Michigan Methods of inactivating bacteria including bacterial spores
US6559189B2 (en) 1999-04-28 2003-05-06 Regents Of The University Of Michigan Non-toxic antimicrobial compositions and methods of use
US6635676B2 (en) 1999-04-28 2003-10-21 Regents Of The University Of Michigan Non-toxic antimicrobial compositions and methods of use
US7767216B2 (en) 1999-04-28 2010-08-03 The Regents Of The University Of Michigan Antimicrobial compositions and methods of use
US6506803B1 (en) 1999-04-28 2003-01-14 Regents Of The University Of Michigan Methods of preventing and treating microbial infections
CA2386270A1 (en) 1999-10-15 2001-04-26 University Of Massachusetts Rna interference pathway genes as tools for targeted genetic interference
US6326193B1 (en) 1999-11-05 2001-12-04 Cambria Biosciences, Llc Insect control agent
US20020061512A1 (en) 2000-02-18 2002-05-23 Kim Jin-Soo Zinc finger domains and methods of identifying same
US20030044787A1 (en) 2000-05-16 2003-03-06 Joung J. Keith Methods and compositions for interaction trap assays
AU2001275474A1 (en) 2000-06-12 2001-12-24 Akkadix Corporation Materials and methods for the control of nematodes
US6555674B2 (en) 2000-08-09 2003-04-29 Nsgene A/S JeT promoter
GB0108491D0 (en) 2001-04-04 2001-05-23 Gendaq Ltd Engineering zinc fingers
EP1476547B1 (en) 2002-01-23 2006-12-06 The University of Utah Research Foundation Targeted chromosomal mutagenesis using zinc finger nucleases
US20030232410A1 (en) 2002-03-21 2003-12-18 Monika Liljedahl Methods and compositions for using zinc finger endonucleases to enhance homologous recombination
US7074596B2 (en) 2002-03-25 2006-07-11 Board Of Supervisors Of Louisiana State University And Agricultural And Mechanical College Synthesis and use of anti-reverse mRNA cap analogues
EP2806025B1 (en) 2002-09-05 2019-04-03 California Institute of Technology Use of zinc finger nucleases to stimulate gene targeting
US8409861B2 (en) 2003-08-08 2013-04-02 Sangamo Biosciences, Inc. Targeted deletion of cellular DNA sequences
US7888121B2 (en) 2003-08-08 2011-02-15 Sangamo Biosciences, Inc. Methods and compositions for targeted cleavage and recombination
JP5139800B2 (ja) 2004-06-03 2013-02-06 ノビミューン エスアー 抗ｃｄ３抗体およびその使用方法
AU2006272634B2 (en) 2005-07-26 2013-01-24 Sangamo Therapeutics, Inc. Targeted integration and expression of exogenous nucleic acid sequences
EP3611266B1 (en) 2005-08-23 2022-11-09 The Trustees of the University of Pennsylvania Rna containing modified nucleosides and methods of use thereof
CA2891996A1 (en) 2005-10-18 2007-04-26 Duke University Rationally-designed meganucleases with altered sequence specificity and dna-binding affinity
EP2215223B1 (en) 2007-10-31 2013-05-01 Precision Biosciences, Inc. Rationally-designed single-chain meganucleases with non-palindromic recognition sequences
EP2206723A1 (en) 2009-01-12 2010-07-14 Bonas, Ulla Modular DNA-binding domains
WO2011059836A2 (en) 2009-10-29 2011-05-19 Trustees Of Dartmouth College T cell receptor-deficient t cell compositions
DK2496698T3 (en) 2009-11-03 2019-04-15 Hope City TRUNCATED EPIDERIMAL GROWTH FACTOR RECEPTOR (EGFRt) FOR TRUNCATED T-CELL SELECTION
US8956828B2 (en) 2009-11-10 2015-02-17 Sangamo Biosciences, Inc. Targeted disruption of T cell receptor genes using engineered zinc finger protein nucleases
HUE041436T2 (hu) 2009-12-10 2019-05-28 Univ Minnesota Tal-effektor-közvetített DNS-módosítás
EP2694089B1 (en) 2011-04-05 2024-06-05 Cellectis New tale-protein scaffolds and uses thereof
GB201206559D0 (en) 2012-04-13 2012-05-30 Ucl Business Plc Polypeptide
WO2013158256A2 (en) 2012-04-20 2013-10-24 Angimmune, Llc Immunomodulation by anti-cd3 immunotoxins to treat cancers not uniformly bearing surface cd3
KR102437522B1 (ko) * 2012-05-25 2022-08-26 셀렉티스 면역요법을 위한 동종이형 및 면역억제제 저항성인 ｔ 세포의 조작 방법
US8697359B1 (en) 2012-12-12 2014-04-15 The Broad Institute, Inc. CRISPR-Cas systems and methods for altering expression of gene products
JP6346266B2 (ja) 2013-03-21 2018-06-20 サンガモ セラピューティクス， インコーポレイテッド 操作されたジンクフィンガータンパク質ヌクレアーゼを使用するｔ細胞受容体遺伝子の標的化された破壊
US10000746B2 (en) 2013-05-31 2018-06-19 Cellectis LAGLIDADG homing endonuclease cleaving the T cell receptor alpha gene and uses thereof
US9790490B2 (en) 2015-06-18 2017-10-17 The Broad Institute Inc. CRISPR enzymes and systems
EP3359660B1 (en) 2015-10-05 2019-12-04 Precision Biosciences, Inc. Engineered meganucleases with recognition sequences found in the human t cell receptor alpha constant region gene
CN117070468A (zh) 2015-10-05 2023-11-17 精密生物科学公司 包含经修饰的人T细胞受体α恒定区基因的经遗传修饰的细胞
IL264502B2 (en) 2016-08-29 2023-09-01 Tiziana Life Sciences Plc Anti-cd3 antibody formulations
ES2925644T3 (es) 2016-10-04 2022-10-19 Prec Biosciences Inc Dominios coestimuladores para su uso en células modificadas genéticamente
US20200239544A1 (en) 2017-10-03 2020-07-30 Precision Biosciences, Inc. Modified epidermal growth factor receptor peptides for use in genetically-modified cells
EP4069285A1 (en) * 2019-12-06 2022-10-12 Precision BioSciences, Inc. Methods for cancer immunotherapy, using lymphodepletion regimens and cd19, cd20 or bcma allogeneic car t cells

Similar Documents

Publication Publication Date Title
Tapia-Galisteo et al. Bi-and trispecific immune cell engagers for immunotherapy of hematological malignancies
Goebeler et al. T cell-engaging therapies—BiTEs and beyond
Duell et al. Bispecific antibodies in the treatment of hematologic malignancies
Guy et al. Bispecific antibodies for the treatment of acute myeloid leukemia
JP7813469B2 (ja) 二重特異性抗体の組成物及びその使用方法
Stein et al. Blinatumomab for acute lymphoblastic leukemia relapse after allogeneic hematopoietic stem cell transplantation
Zekri et al. An IgG‐based bispecific antibody for improved dual targeting in PSMA‐positive cancer
Shabaneh et al. Systemically administered low-affinity HER2 CAR T cells mediate antitumor efficacy without toxicity
Aldoss et al. Redirecting T cells to eradicate B-cell acute lymphoblastic leukemia: bispecific T-cell engagers and chimeric antigen receptors
Abou Dalle et al. Bi-and Tri-specific antibodies in non-Hodgkin lymphoma: current data and perspectives
EP3703710B1 (en) Methods and compositions for dosing of allogeneic chimeric antigen receptor t cells for treating refractory and/or relapsed large b-cell lymphoma or refractory and/or relapsed follicular lymphoma
JP2015163068A5 (https=)
JP2009502171A5 (https=)
Yeku et al. Bispecific T-cell engaging antibodies against MUC16 demonstrate efficacy against ovarian cancer in monotherapy and in combination with PD-1 and VEGF inhibition
AU2021315882A1 (en) Compositions including ex vivo armed T cells with multi-specific antibodies and uses thereof
JP2020502147A (ja) 制御性ｂ１０細胞を枯渇させる抗体および方法並びに免疫チェックポイント阻害剤との併用における使用
Castaneda-Puglianini et al. Bispecific antibodies for non-Hodgkin’s lymphomas and multiple myeloma
WO2023161943A1 (en) Humanized antibodies against nectin-2 and drug conjugates thereof
Wang et al. An optimal antitumor response by a novel CEA/CD3 bispecific antibody for colorectal cancers
JP2025175307A (ja) 逐次抗ｃｄ１９治療
Zarnani et al. Monoclonal antibodies for cancer immunotherapy
Morabito et al. Comparative analysis of bispecific antibodies and CAR T‐cell therapy in Follicular lymphoma
JPWO2021035054A5 (https=)
Hoseini et al. Overcoming leukemia heterogeneity by combining T cell engaging bispecific antibodies
JPWO2020113188A5 (https=)